WBC
NBIX icon

Westpac Banking Corp’s Neurocrine Biosciences NBIX Stock Holding History

Westpac Banking Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
1,615
+91
+6% +$12.1K 0.01% 360
2025
Q4 		$216K Sell
1,524
-6
-0.4% -$869 0.01% 346
2025
Q3 		$215K Sell
1,530
-2,698
-64% -$366K 0.01% 334
2025
Q2 		$531K Sell
4,228
-56
-1% -$6.42K 0.04% 256
2025
Q1 		$474K Sell
4,284
-9,705
-69% -$1.23M 0.03% 261
2024
Q4 		$1.91M Buy
13,989
+1,429
+11% +$177K 0.13% 163
2024
Q3 		$1.45M Buy
12,560
+6,170
+97% +$846K 0.1% 194
2024
Q2 		$880K Sell
6,390
-396
-6% -$54.3K 0.07% 209
2024
Q1 		$936K Hold
6,786
– – 0.07% 210
2023
Q4 		$894K Buy
6,786
+4,805
+243% +$553K 0.07% 204
2023
Q3 		$223K Sell
1,981
-287
-13% -$30.2K 0.02% 369
2023
Q2 		$214K Sell
2,268
-4,828
-68% -$472K 0.02% 362
2023
Q1 		$718K Hold
7,096
– – 0.01% 702
2022
Q4 		$848K Hold
7,096
– – 0.01% 640
2022
Q3 		$754K Hold
7,096
– – 0.01% 667
2022
Q2 		$692K Hold
7,096
– – 0.01% 718
2022
Q1 		$665K Hold
7,096
– – 0.01% 748
2021
Q4 		$604K Hold
7,096
– – 0.01% 768
2021
Q3 		$681K Hold
7,096
– – 0.01% 772
2021
Q2 		$691K Hold
7,096
– – 0.01% 795
2021
Q1 		$690K Hold
7,096
– – 0.01% 745
2020
Q4 		$680K Hold
7,096
– – 0.01% 788
2020
Q3 		$682K Hold
7,096
– – 0.01% 747
2020
Q2 		$866K Hold
7,096
– – 0.01% 673
2020
Q1 		$614K Hold
7,096
– – 0.01% 691
2019
Q4 		$763K Buy
+7,096
New +$743K 0.01% 741

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Westpac Banking Corp's NBIX Position: Q1 2026 in Review

Westpac Banking Corp increased its Neurocrine Biosciences (NBIX) stake by 6% in Q1 2026, buying an estimated $12.1K and bringing the position to 1,615 shares worth $213K. The position accounts for 0.01% of the portfolio, ranked #360.

Westpac Banking Corp first reported a position in NBIX in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.91M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Westpac Banking Corp held 1,615 shares of Neurocrine Biosciences worth $213K as of Q1 2026.
  • Westpac Banking Corp bought 91 Neurocrine Biosciences shares in Q1 2026, an estimated $12.1K.
  • Neurocrine Biosciences made up 0.01% of Westpac Banking Corp's portfolio in Q1 2026, its #360 holding.
  • Westpac Banking Corp first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 26 quarters since.
  • Westpac Banking Corp's Neurocrine Biosciences position peaked at $1.91M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Westpac Banking Corp's 13F filing for Q1 2026, filed 12 May 2026.